T&R Biofab Co. Ltd (246710) - Total Liabilities
Based on the latest financial reports, T&R Biofab Co. Ltd (246710) has total liabilities worth ₩72.55 Billion KRW (≈ $49.17 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
T&R Biofab Co. Ltd - Total Liabilities Trend (2015–2024)
This chart illustrates how T&R Biofab Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See how liquid is T&R Biofab Co. Ltd's working capital to evaluate short-term liquidity relative to the company's equity base.
T&R Biofab Co. Ltd Competitors by Total Liabilities
The table below lists competitors of T&R Biofab Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PharmGen Science Inc
KO:004720
|
Korea | ₩83.70 Billion |
|
TPXIMPACT HOLDINGS LS-01
F:9L7
|
Germany | €17.56 Million |
|
Cheil Grinding
KO:001560
|
Korea | ₩12.41 Billion |
|
GenMont Biotech Inc
TW:3164
|
Taiwan | NT$215.35 Million |
|
TJGC Group Limited
NASDAQ:TJGC
|
USA | $2.18 Million |
|
Hwacheon Machi
KO:010660
|
Korea | ₩45.75 Billion |
|
GeneFerm Biotechnology Co Ltd
TWO:1796
|
Taiwan | NT$453.10 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down T&R Biofab Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see T&R Biofab Co. Ltd market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 6.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.87 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how T&R Biofab Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for T&R Biofab Co. Ltd (2015–2024)
The table below shows the annual total liabilities of T&R Biofab Co. Ltd from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩74.24 Billion ≈ $50.31 Million |
+8.19% |
| 2023-12-31 | ₩68.62 Billion ≈ $46.50 Million |
+87.10% |
| 2022-12-31 | ₩36.67 Billion ≈ $24.85 Million |
-9.54% |
| 2021-12-31 | ₩40.54 Billion ≈ $27.47 Million |
+1552.73% |
| 2020-12-31 | ₩2.45 Billion ≈ $1.66 Million |
+5.25% |
| 2019-12-31 | ₩2.33 Billion ≈ $1.58 Million |
+178.40% |
| 2018-12-31 | ₩837.09 Million ≈ $567.28K |
+111.68% |
| 2017-12-31 | ₩395.46 Million ≈ $268.00K |
-46.44% |
| 2016-12-31 | ₩738.36 Million ≈ $500.38K |
-60.60% |
| 2015-12-31 | ₩1.87 Billion ≈ $1.27 Million |
-- |
About T&R Biofab Co. Ltd
T&R Biofab Co., Ltd. develops and commercializes various regenerative medical technologies. It offers 3D-printed medical devices; and bio-surgical solutions, which includes wound dressing and acellular dermal matrix, as well as biomaterials and biopharmaceuticals. The company was founded in 2013 and is based in Siheung-si, South Korea.